Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD

American Journal of Kidney Diseases

Volumn 45, Issue 3, 2005, Pages

  Yang, Kai Chien ^a   Fang, Cheng Chung ^a   Su, Ta Chen ^a   Lee, Yuan Teh ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bezafibrate; End stage renal disease (ESRD); Plasma exchange; Rhabdomyolysis

Indexed keywords

BEZAFIBRATE; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; TRIACYLGLYCEROL; WARFARIN;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LABORATORY; PARAMETER; PLASMAPHERESIS; RHABDOMYOLYSIS; SAFETY;

EID: 14844302638     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.12.003     Document Type: Article

References (14)

1. E.J. de Koning, T.J. Rabelink Endothelial function in the post-prandial state Atheroscler 3 suppl 2002 11 16
2. V. Panuccio, G. Enia, S. Parlongo, S. Cutrupi, C. Zoccali Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient Nephron 73 1996 736
3. P.L. Bedani, L. Perini, P. Gilli Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis Nephron 68 1994 512 513
4. J. Weissgarten, R. Zaidenstein, S. Fishman Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs? Perit Dial Int 19 1999 180 182
5. C.M.E. Vergani, G. Vigotti, G.L. Fiorini Pharmacokinetics of bezafibrate in hyperlipoproteinaemic patients G. Crepaldi Lipoprotein Metabolism and Therapy of Lipid Disorders 1982 Excerpta Medica Amsterdam, The Netherlands 79 82
6. C.G. Ericsson, A. Hamsten, J. Nilsson, L. Grip, B. Svane, U. de Faire Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients Lancet 347 1996 849 853
7. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
8. A. Haubenstock, W. Schrocksnadel, K. Bauer, P. Schmidt, F. Gabl Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis Clin Chem 30 1984 1587 1588
9. H. Teravainen, A. Larsen, M. Hillbom Clofibrate-induced myopathy in the rat Acta Neuropathol (Berl) 39 1977 135 138
10. P. Grutzmacher, E. Scheuermann, D. Lang Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients Proc Eur Dial Transplant Assoc 18 1981 169 175
11. P. Grutzmacher, E.H. Scheuermann, W. Siede Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis Pharmacokinetics and effects Klin Wochenschr 64 1986 910 916
12. J.P. Monk, P.A. Todd Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia Drugs 33 1987 539 576
13. F. Keller, U. Faber, S. Reeck Effect of toxicity of bezafibrate in hemodialysis patients Clin Nephrol 28 1987 159 160
14. T.T. Chrisafghi, J.M. Haralampos, S.E. Moses Acute rhabdomyolysis after bezafibrate re-exposure Nephron 78 1998 336 337